Catalyst Wire Dossier Catalyst Wire Dossier

PG286 ophthalmic solution 0.5%

PG286 · Aerie Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PG286 ophthalmic solution 0.5%, covering 2014-03-17 to 2014-03-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days [Phase 2]

See pricing